biote (NASDAQ:BTMD) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Key Points

• Q4 beat: biote reported $0.06 EPS, beating estimates by $0.01, and revenue of $46.41 million versus $45.79 million, though it showed a negative return on equity (21.86%) with a net margin of 14.72%.
• Shares traded at $1.72 (market cap $78.54M) with a low PE of 2.18, while analysts are mixed — consensus rating "Hold" with an average target price of $5.67 (one Buy, one Hold, one Sell).
• Institutional investors own about 21.68% of the stock, with recent buys by Geode, State Street, Renaissance and Bridgeway, and biote operates the Biote Method practice-building platform for hormone optimization clinicians.

biote (NASDAQ:BTMD - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.05 by $0.01, FiscalAI reports. The firm had revenue of $46.41 million for the quarter, compared to analyst estimates of $45.79 million. biote had a negative return on equity of 21.86% and a net margin of 14.72%.

biote Stock Performance

Shares of BTMD stock traded up $0.02 on Wednesday, hitting $1.72. 228,260 shares of the stock traded hands, compared to its average volume of 168,190. The firm's 50-day moving average price is $2.21 and its two-hundred day moving average price is $2.66. The stock has a market capitalization of $78.54 million, a PE ratio of 2.18 and a beta of 1.14. biote has a twelve month low of $1.68 and a twelve month high of $4.75.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on BTMD shares. Truist Financial set a $5.00 target price on shares of biote in a report on Wednesday, January 7th. Weiss Ratings reissued a "sell (d+)" rating on shares of biote in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $5.67.

Hedge Funds Weigh In On biote

A number of institutional investors have recently bought and sold shares of BTMD. Geode Capital Management LLC boosted its holdings in biote by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 620,256 shares of the company's stock valued at $1,613,000 after purchasing an additional 8,016 shares during the last quarter. State Street Corp increased its holdings in shares of biote by 17.3% during the 4th quarter. State Street Corp now owns 600,114 shares of the company's stock worth $1,560,000 after buying an additional 88,402 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of biote by 5.7% during the 4th quarter. Renaissance Technologies LLC now owns 203,594 shares of the company's stock valued at $529,000 after buying an additional 10,900 shares during the period. Rothschild Wealth LLC purchased a new stake in shares of biote during the 4th quarter valued at approximately $380,000. Finally, Bridgeway Capital Management LLC lifted its holdings in biote by 142.1% in the second quarter. Bridgeway Capital Management LLC now owns 121,053 shares of the company's stock valued at $487,000 after acquiring an additional 71,053 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.